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The immune responses to an HIV-1 p55Gag vaccine encoded as a DNA chimera with the lysosomal associated membrane protein-1
(LAMP) have been examined for the effect of the addition of the inverted terminal repeat (ITR) sequences of the adeno-associated virus
(AAV) to the DNA plasmid construct, and of packaging the LAMP/gag gene as a recombinant AAV vector (rAAV). DNA plasmids encoding
Gag and the LAMP/Gag protein chimera were constructed in two vectors, the pcDNA3.1 and a corresponding plasmid containing the ITR
sequences (pITR) flanking the expression elements of the plasmid, and the pITR LAMP/gag DNA plasmid was encapsidated in the rAAV
vector. Human 293 cells transfected in vitro with LAMP/gag plasmids either in pcDNA3.1 or pITR produced much Gag protein in cell
extracts (1.6 and 2.2 ng of Gag/mg of protein, respectively). The immune responses of mice to immunization with these constructs were
examined under three protocols: DNA prime/DNA boost, DNA prime/rAAV boost, and a single rAAV immunization. The results
demonstrated that under DNA prime/DNA boost protocol, the ‘‘naked’’ DNA vaccines encoding the LAMP/gag chimera, either as
pcDNA3.1 or pITR DNA plasmid constructs, elicited strong CD4+ T cell responses. In contrast, significantly higher levels of CD8+ and
antibody responses were observed with the pITR-DNA constructs. Immunization with the rAAV vector under the DNA prime/rAAV boost
protocol resulted in sustained T cell responses and a markedly increased antibody response, predominantly of the IgG1 isotype resulting from
the activation of the Th2 subset of CD4+ T cells, that was sustained for at least 5 months after immunization.
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Introduction sequence and bracketed by the adeno-associated virusWe recently described mouse immune responses to an
HIV-1 Gag DNA plasmid vaccine containing the p55gag
gene inserted into the luminal domain of the complete
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LAMP/gag) (Marques et al., 2003). Cultured cells trans-
fected with pITR/LAMP/gag expressed high levels of
LAMP/Gag protein chimera that trafficked to a vesicular
site where LAMP was colocalized with the endogenous
major histocompatibility class II (MHC II) molecule of
antigen presenting cells (APCs). Mice injected with this
DNA plasmid produced strong cellular and humoral immune
responses as compared to the response to DNA encoding
native p55Gag, with a 10-fold increase in CD4+ responses, a
4- to 5-fold increase in CD8+ T-cell responses, and antibody
titers >100,000. Ongoing studies of ‘‘naked’’ DNA immu-
nization of monkeys have also shown strong humoral and
cellular responses (Chikhlikar et al., unpublished). These
P. Chikhlikar et al. / Virology 323 (2004) 220–232 221effects of the pITR/LAMP/gag DNA are novel findings with
respect to both p55Gag expression and the immune response
to the LAMP/Gag chimera protein.
The structure and biology of DNA plasmid constructs
containing ITR sequences differ markedly from that of
AAV virus and recombinant AAV (rAAV) vectors, and
there is evidence that the ITR sequences of double-strand-
ed, linear plasmid DNA do not act as an agent for
chromosomal integration. In nature, the 145-bp ITR
sequences flank the AAV parvovirus genome, a single-
stranded DNA encoding the viral replication and capsid
components, and are cis-acting elements required for
packaging, integration, and replication (Xiao et al.,
1997). Wild-type AAV establishes a latent infection by
integrating into human chromosome 19 (Kotin et al.,
1991). In contrast, rAAV vectors, lacking the viral genes
that mediate site-specific integration, act chiefly as extra-
chromosomal episomes with high levels of transgene
expression that persist for more than a year (Hsiao et al.,
2001). The incoming single-stranded vector genome is
converted into various forms of double-stranded linear
and circular monomers and can also form high molecular
weight concatemers; a small fraction of which may inte-
grate randomly into chromosomes. The circularized epi-
somes consist mainly as head-to-tail monomers that slowly
convert to large concatemers as a result of intermolecular
recombination of the monomer viral genomes (Duan et al.,
1998, 1999; Yang et al., 1999). While it is reported that
DNA concatemers can form from independent monomers
of circular viral genomes (Yang et al., 1999), others have
proposed a model whereby interaction of double-stranded
linear molecules is the predominant pathway for intermo-
lecular recombination of rAAV vector genomes (Chen et
al., 2001; Nakai et al., 2003a, 2003b, 2003c, 2003d; Yue
and Duan, 2003). Data also show that circularization
results from DNA-dependent protein kinase (DNA-PK)
catalyzed recombination between free ends of the double-
stranded linear rAAV DNA (Song et al., 2001). The
formation of concatemers in these studies was independent
of ITR sequences. The presence or the absence of ITR
sequences made no difference on transgene expression or
on DNA molecular structures in treated animals. Moreover,
the linear DNA molecules integrated into chromosomes of
mouse hepatocytes in vivo at a level of less than one
vector genome per diploid genomic equivalent, irrespective
of the presence or absence of ITR sequences (Nakai et al.,
2003c). Free DNA ends, not ITR sequences, are likely
substrates for concatemerization and DNA integration.
Thus, the double-stranded, circular, supercoiled pITR
DNA of the pITR/LAMP/gag construct can be expected
to have fundamentally different transgene biology as com-
pared to the single-stranded linear DNA of the rAAV
vector concerning genomic integration.
The focus of this report is the effect of AAV ITR
sequences on the immunogenicity of a LAMP/gag chimera
genetic vaccine when delivered as ‘‘naked’’ plasmid DNAand as linear DNA encapsided in the rAAV vector system.
We have analyzed the immune responses of mice to vacci-
nation with pcDNA3.1 and pITR ‘‘naked’’ DNA plasmids
encoding the LAMP/gag chimera, and to vaccination with
the pITR LAMP/gag construct packaged into the rAAV
vector. The pITR DNA plasmids and rAAV vector each
contain the same LAMP and gag sequences but are distin-
guished by several structural differences. Prominent among
these is that the pITR plasmid is produced in Escherichia coli
as circular, supercoiled double-stranded DNA, whereas the
rAAV vector is packaged in mammalian cells by the AAV
capsid protein as a linear single-stranded DNA. The results
demonstrate distinct differences in the immune responses to
these diverse forms of genetic vaccine and provide evidence
for an effect of the ITR sequence on the antibody and CTL
response of the LAMP/gag immunized mice.Results
Gag expression in vitro by cells transfected with pcDNA3.1
and pITR plasmid constructs encoding p55gag and
LAMP/gag chimera
Eukaryotic expression plasmids were constructed as
described in Materials and methods using p55gag gene
inserted into two vectors, pcDNA3.1 (Invitrogen, San
Diego, CA) and pITR (Kessler et al., 1996), a vector
containing the adeno-associated virus inverted terminal
repeat (AAV-ITR) sequences flanking the expression ele-
ments (Fig. 1). Gag expression by transfected human 293
cells was examined by Western blot analyses (Fig. 2A) and
antigen-specific ELISA quantification of Gag protein (Fig.
2B). There was very little transgene expression of p55gag,
about 100 and 400 pg p24/mg protein in extracts of
pcDNA3.1/gag and pITR/gag transfected cells, respectively
(Fig. 2, lanes 3 and 8). HIV-1 Gag expression is known to
be limited in the absence of HIV-1 Rev protein by mRNA
cis-acting inhibitory sequences (Maldarelli et al., 1991;
Nasioulas et al., 1994). Other workers have overcome this
limitation by DNA sequence humanization or mutation to
remove the inhibitory sequences (Deml et al., 2001; Huang
et al., 2001; Kotsopoulou et al., 2000; Qiu et al., 1999;
Schneider et al., 1997; zur Megede et al., 2000). This
limitation in the expression of unmodified Gag is also
overcome when encoded as the LAMP/gag chimera (Mar-
ques et al., 2003). In repeated experiments with cells trans-
fected with the pcDNA3.1 plasmids, the expression of the
LAMP/Gag chimera was about 20 times greater than ex-
pression of native Gag (Fig. 2, lanes 3 and 4). Moreover, the
expression of LAMP/Gag and Gag was consistently further
increased when the ITR sequences were added to the
expression plasmid (pITR) (Fig. 2, lanes 7 and 8). The high
level expression of Gag as a LAMP/Gag chimera is attrib-
uted to the transcription elements of LAMP overcoming the
negative effect of the downstream gag sequences (unpub-
Fig. 1. Schematic representations of plasmids encoding gag and LAMP/gag
genes. HIV-1 gag expression constructs used in these studies in pcDNA3.1
and pITR plasmids: pcDNA 3.1 encoding native gag (pcDNA3.1/gag);
pcDNA 3.1 encoding native gag as a chimera inserted proximal to the
transmembrane domain of the complete LAMP cDNA (pcDNA3.1/LAMP/
gag); pITR encoding native gag (pITR/gag); pITR encoding native gag as a
chimera inserted proximal to the transmembrane domain of the complete
LAMP cDNA (pITR/LAMP/gag). Boxed areas represent the open reading
frames as indicated. Ovals indicate the AAV-ITR sequences. Arrows
indicate the schematic position of the various sequences: LAMP lumen, the
lumenal domain of LAMP (filled box); gag, the native p55gag sequence
(clear box) and TM/Cyto., the LAMP transmembrane and cytoplasmic
domains (filled box).
Fig. 2. HIV-Gag expression and quantification. (A) Western blot analysis.
Human 293 cells transfected with plasmids as indicated at the bottom of the
graph and probed with anti-Gag monoclonal antibody. The molecular
weight markers are indicated on the left side. (B) Quantitative Gag p24
capture ELISA. The Gag protein expression was quantified in cell extracts
of human 293 cells transfected with the plasmids indicated at the bottom as
described in Materials and methods. The protein expression was normalized
by the total protein concentration of the extract. Representative experiment
is shown as mean F SD.
P. Chikhlikar et al. / Virology 323 (2004) 220–232222lished data). The increased Gag expression associated with
the pITR constructs may be related to recognition of the ITR
sequences by nuclear regulatory elements (Chou et al.,
2001; Fu et al., 1999; Xin et al., 2003).
CD4+ responses to ‘‘naked’’ DNA immunizations with
pcDNA3.1 and pITR plasmid vectors encoding p55gag and
the LAMP/gag chimera
The effect of AAV-ITR sequences on the immune re-
sponse to DNA vaccines was studied by comparing the
responses to immunizations with pcDNA3.1 and pITR
plasmids encoding native p55gag and the LAMP/gag chi-
mera. Mice were immunized on days 1 and 21 with 50 Ag
DNA in groups of six animals for each construct: (1)
Control LAMP construct without gag sequences, (2) the
native HIV-1 gag construct, and (3) HIV-1 LAMP/gag
construct with gag incorporated into the complete LAMP-
1 immediately proximal to the LAMP transmembrane
domain. All three constructs were synthesized in both
pcDNA3.1 and pITR plasmids.
Following the two immunizations, mice were sacrificed
and their splenocytes were prepared for assays of CD4+ T-
cell IFN-g responses as described in Materials and methods.
Previous experiments have shown that the IFN-g response
of cells stimulated by incubation with the recombinant HIV-
1 Gag protein was blocked by anti-CD4+ but not anti-CD8+
specific monoclonal antibody (Marques et al., 2003). The
MHC II-targeted LAMP/gag constructs, both in thepcDNA3.1 and pITR plasmids, elicited comparable IFN-g
CD4+ responses that were much stronger than the responses
to the corresponding plasmids encoding native gag (Fig. 3).
CD8+ immune responses assayed by tetramer binding,
intracellular IFN-c staining, and cell cytotoxicity
Assays of CD8+ T cell responses were carried out with
mice immunized once with 50 Ag of the plasmid DNA,
followed in 3 weeks by in vivo expansion of Gag-specific T-
cells through inoculation with recombinant vaccinia-Gag-
Pol (rVVGag-Pol). Five days later, the mice were injected
with an immunodominant H-2Kd-restricted Gag peptide
epitope; after 2 h they were sacrificed, spleen cells were
prepared, and the CD8+ T cells assayed ex vivo. In contrast
to the relatively equal CD4+ response to the two plasmid
Fig. 3. CD4+ immune responses. CD4+ IFN-g secretion from splenocytes of
mice injected with the indicated plasmids. Mice (2–3/group) were injected
im with 50 Ag DNA on days 1 and 21 with pcDNA3.1 or pITR plasmids
encoding the control LAMP (LAMP), native p55Gag control (gag), and the
LAMP/Gag chimera in the complete LAMP sequence (LAMP/gag).
Animals were sacrificed on day 31 and splenocytes were prepared for
assay of CD4+ T-cell responses as described in Materials and methods and
incubated in the absence (empty bars) and the presence (black bars) of
antigen. Representative experiment is shown as mean F SD.
P. Chikhlikar et al. / Virology 323 (2004) 220–232 223constructs, mice uniformly developed significantly stronger
CD8+ responses to pITR/LAMP/gag DNA than to the
corresponding pcDNA3.1 construct (Fig. 4). The immune
responses measured by epitope-specific CD8+ tetramer
binding and intracellular IFN-g staining were 3-fold and
18-fold higher, respectively, in response to the pITR/LAMP/Fig. 4. CD8+ immune responses. Mice (2–3/group) were immunized im with 50
injected ip with 107 PFU of rVV-gag-pol. Five days later, 10 Ag of the H-2Kd-bind
2 h and analyzed ex vivo. (A) Flow cytometry quantification of Gag-specific CD
tetramer binding in the CD8+ splenic population. (C) Cytolytic activity in a 4-h 51C
Gag peptide. The effector cells from the different immunized mice were used as ind
groups (not shown). Representative experiment is shown as mean F SD.gag construct than the responses to pcDNA3.1/LAMP/gag.
Additionally, CTL lysis of peptide pulsed target cells was
much greater with cells from the pITR/LAMP/gag immu-
nized mice. The large fraction of CD8+ T cells expressing
IFN-g (18%) following inoculation with recombinant vac-
cinia virus encoding Gag is attributed to the massive in vivo
expansion of Gag-activated CD8+ T cells reactive against
several Gag MHC class I epitopes. A smaller fraction of the
CD8+ T population responded to the specific H-2Kd-
AMQMLKETI peptide-tetramer epitope complex.
Effect of multiple immunizations on anti-Gag IgG responses
Mice were immunized on days 1, 30, 60, and 90 with 50
Ag DNA of the pcDNA3.1 and pITR plasmid vectors
encoding Gag and the LAMP/Gag chimera. Blood was
collected after on days 59, 89, and 119 (after the second,
third, and fourth immunizations) for analysis of the total
anti-Gag IgG responses (Fig. 5). Small increases in
responses to the third and fourth immunization were ob-
served with wild-type gag and LAMP/gag encoded in the
pcDNA3.1 plasmid. In contrast, the response to the pITR/
LAMP/gag immunization was much greater and was max-
imal after the 2nd immunization.
rAAV packaging of pITR/LAMP/gag construct, assay
of DNAse-resistant genomic copies, and LAMP/Gag
expression by transduced cells
The preceding data showed that DNA immunization with
the pITR/LAMP/gag construct elicited stronger CD8+ T cell
and antibody responses than did the corresponding constructAg of the indicated pcDNA3.1 and pITR plasmids. On day 21, they were
ing HIV-1 Gag peptide was injected iv, and splenocytes were harvested after
8+ T-lymphocytes producing IFN-g. (B) Flow cytometric quantification of
r release assay using P815 target cells pulsed with the H-2Kd-binding HIV-1
icated. Nonspecific lysis (using unpulsed P815 target cells) was < 5% for all
Fig. 5. Humoral responses. Mice were injected im on days 1, 30, 60, and 90 with 50 Ag (A) pcDNA3.1 or (B) pITR plasmid DNA encoding gag or LAMP/gag
as indicated. Samples were collected a day before each immunization. Each titration curve indicates the OD450nm of Gag-specific total IgG present in serial
dilutions of pooled serum from individual groups of mice.
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conducted to compare the immune responses induced by
the pITR/LAMP/gag construct as ‘‘naked’’ DNA or when
packaged into the rAAV delivery system. Adenovirus-
infected human 293 cells were transfected with the pITR/
LAMP/gag DNA and the rAAV vector was prepared as
described in Materials and methods. The purified particles
were tested to be free of replication competent AAV and
adenovirus. Quantitative real-time PCR (qPCR) was used to
determine the concentration of genomic copies of the pITR/
LAMP/gag rAAV DNAse-resistant particles. The purified
rAVV suspension was digested with protease K and the
rAAV LAMP/gag genomic copies were quantified using
primers designed to hybridize with gag-specific sequences.
A sample of the purified rAAVmaterial was resuspended and
diluted 1 to 10 and 10 Al used for each qPCR reaction. The
purified particles contained 1012 genomic copies/ml as
compared to a standard curve with ‘‘naked’’ plasmid DNA
(Fig. 6A). The efficiency of cell transduction in vitro by the
purified rAAV particles containing the LAMP/gag gene wasFig. 6. rAAV vector quantification and expression. (A) qPCR standard curve of ga
shows the linear regression analyses, and the gray lines represents the 95% confid
(filled square) was related to a standard curve as shown in the figure, and the numb
cell extracts from cells were transduced with the rAAV-LAMP/gag plasmid and pr
indicated on the left side.tested in 293 cells (Fig. 6B). It is well known that the
transduction of cells by rAAV viral vectors is much more
efficient than transfection with plasmid DNA. Cells incubat-
ed for 48 h with 5  109 particles, containing approximately
10 ng single-stranded DNA encoding LAMP/Gag, were
analyzed by Western blot. The level of LAMP/Gag expres-
sion was comparable to that obtained from cells transfected
with 4 Ag DNA and FuGene-6 transfection reagent.
Comparison of the early and late immune responses to
different DNA prime and rAAV boost protocols
Additional studies compared the immune responses to
pITR/LAMP/gag delivered by ‘‘naked’’ DNA plasmid and
by the rAAV vector. A complication in the use of an rAAV
vector for vaccine delivery is the risk of a host immune
response to multiple injections of the AAV capsid protein
(Chirmule et al., 2000; Xiao et al., 1999). For this reason,
the protocols of this study were designed for a single
injection of the rAAV vector.g genomic copies. Open circles indicate the standard samples, the black line
ence interval of the standard curve. The qPCR curve of rAAV/LAMP/gag
er of genomic copies was calculated. (B) Western blot analyzes. Human 293
obed with anti-gag monoclonal antibody. The molecular weight markers are
Fig. 7. CD4+ immune responses at week 6 to ‘‘naked’’ DNA and rAAV. Mice were injected im once with pITR/LAMP (control); with 1  109 particles of
LAMP/gag rAAV (AAV); primed with 50 Ag pITR/LAMP/gag DNA and boosted on day 21 with 1  109 particles of LAMP/gag rAAV (DNA/AAV); or
injected twice with 50 Ag pITR/LAMP/gag DNA (DNA/DNA). (A) Splenocyte CD4+ IFN-g secretion. (B) Splenocyte IL-4 mRNA upregulation. Animals
were sacrificed on day 42 and splenocytes were prepared for assay of CD4+ T-cell responses as described in Materials and methods and incubated in the
absence (empty bars) and presence (black bars) of antigen. Representative experiment is shown as mean F SD.
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(im) at day 1 for prime and day 21 for boost with either 50
Ag DNA or 109 rAAV particles as follows: (1) pITR/LAMP
DNA prime and wild-type rAAV boost, both lacking gag
sequences, as the negative control (control); (2) the standard
two ‘‘naked’’ DNA immunizations with the pITR/LAMP/
gag plasmid (DNA/DNA); (3) pITR/LAMP/gag DNA
prime and rAAV/ITR/LAMP/gag boost (DNA/rAAV); and
(4) a single immunization with rAAV/ITR/LAMP/gag
(rAAV). Blood samples were collected for antibody
responses and animals were sacrificed on weeks 6, 23,
and 29 following the boost immunization on week 3 (day
21) for assays of CD4+ (Figs. 7 and 8) and CD8+ (Fig. 9) T-
cell responses.
The early Gag-specific CD4+-mediated responses of
mouse spleen cells were assayed at week 6, 3 weeks afterFig. 8. CD4+ immune responses at week 23 to ‘‘naked’’ DNA and rAAV. Mice w
LAMP/gag rAAV (AAV); primed with 50 Ag pITR/LAMP/gag DNA and booste
injected twice with 50 Ag pITR/LAMP/gag DNA on days 1 and 21 (DNA/DN
upregulation. Animals were sacrificed at week 23 and splenocytes were prepared fo
incubated in the absence (empty bars) and presence (black bars) of antigen. Reprthe second immunization (Fig. 7). Mice of each experimen-
tal group, DNA/DNA, DNA/rAAV, and rAAV, all receiving
the same pITR LAMP/gag DNA sequence, registered strong
CD4+ IFN-g protein and IL-4 mRNA responses. The
strongest of these early responses were of mice immunized
twice with the pITR/LAMP/gag DNA (DNA/DNA), with 2-
to 3-fold higher IFN-g protein production and 6- to 10-fold
higher IL-4 cytokine mRNA expression than the responses
elicited by DNA prime and rAAV boost (DNA/rAAV), and
rAAV prime alone. The strong early CD4+ responses to
DNA/DNA immunization have been confirmed by multiple
applications of this protocol in other studies currently being
conducted (Marques et al., 2003).
Long-term T cell responses were measured at week 23
for CD4+ and at week 29 for CD8+. The CD4+ responses
continued to be significant, particularly with the DNA/ere injected im once with pITR/LAMP (control); with 1  109 particles of
d on day 21 with 1  109 particles of LAMP/gag rAAV (DNA/AAV); or
A). (A) Splenocyte CD4+ IFN-g secretion. (B) Splenocyte IL-4 mRNA
r assay of CD4+ T-cell responses as described in Materials and methods and
esentative experiment is shown as mean F SD.
Fig. 9. CD8+ immune responses comparing ‘‘naked’’ DNA and rAAV at week 29. Mice were injected im once with pITR/LAMP (control); with 1  109
particles of LAMP/gag rAAV (AAV); primed with 50 Ag pITR/LAMP/gag DNA and boosted on day 21 with 1  109 particles of LAMP/gag rAAV (DNA/
AAV); or injected twice with 50 Ag pITR/LAMP/gag DNA (DNA/DNA). Mice were injected ip with 107 PFU of rVV-gag-pol 5 days before sacrifice. On the
day of sacrifice, 10 Ag of the H-2Kd-binding HIV-1 Gag peptide was injected iv, and splenocytes were harvested after 2 h and analyzed ex vivo. (A) %IFN-g+/
CD8+ staining of splenocytes. Animals were sacrificed and splenocytes were prepared for assay of CD8+ T-cell responses as described in Materials and
methods and incubated in the absence (empty bars) and the presence (black bars) of antigen. (B) Percent Tetramer+/CD8+ staining of splenocytes from mice
injected with the indicated schedules. The empty bars represent control staining and black bars the H-2d Gag peptide tetramer staining. Representative
experiment is shown as mean F SD.
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decline in IFN-g protein response at week 23 as com-
pared to week 6 (4 vs. 5 ng/ml, respectively) (Fig. 8).
Notably, however, the IL-4 mRNA response to DNA/
DNA immunization at week 6 was markedly reduced to
background level at week 23. This was accompanied, as
shown below, by a corresponding reduction over this time
of Gag-specific IgG response, indicative of a limited
duration of IL-4 cytokine expression and Ig humoral
responses as compared to IFN-g protein response. At
week 29, there was continued elevation of CD8+ IFN-g
intracellular staining and tetramer responses to the DNA/
rAAV vaccinations with a high fraction of total CD8+ T
cells capable of responding to antigen activation (Fig. 9).
The smaller tetramer-binding response to the DNA/DNA
protocol as compared to the DNA/rAAV is to be
explained. Ongoing experiments suggest that differentTable 1
Gag-specific IgG antibody responses
Vaccine Reverse IgG titer
Week 0 Week 9 We
rAAV (LzAMP) 0 <100 <
rAAV
(LzAMP/gag)
0 2700 24,
DNA-rAAzV
(LAMP/gag)
0 >2z1z8,
7z0z0
72,
DNA-DzNzA
(LAMP/gag)
0 72,900 24,
Mice were injected im once with pITR/LAMP (control); with 1  109 particles o
boosted on day 21 with 1  109 particles of LAMP/gag rAAV (DNA/AAV); or i
collected by tail bleed and serum samples were prepared in eight (3-fold) serial dilu
goat anti-mouse anti-IgG-horseradish peroxidase. The IgG antibody responses werepertoires of epitopes may be elicited depending on the
types of antigen-presenting cells activated by the DNA
and the intracellular route of trafficking of the encoded
antigen. It appears that a higher proportion of memory T-
cells elicited by DNA prime, rAAV boost immunization
recognize or have a higher affinity for the AMQMLKETI-
MHC I tetramer than do the T cell responding to this
epitope and induced by DNA/DNA immunization. Immu-
nization with a single dose of rAAV was least effective in
eliciting CD4+ and CD8+ responses, particularly when
compared to the response to a single AAV boost follow-
ing DNA prime.
Gag-specific antibody responses were examined every
5 weeks for 7 months, starting at week 9 (Table 1). The
peak response elicited by the DNA/rAAV protocol was
markedly greater (>218,700) and more sustained than
those of the DNA/DNA (72,900) and rAAV primeek 14 Week 19 Week 23 Week 28
100 <100 <100 <100
300 2700 900 <100
900 72,900 24,300 24,300
300 8100 2700 2700
f LAMP/gag rAAV (AAV); primed with 50 Ag pITR/LAMP/gag DNA and
njected twice with 50 Ag pITR/LAMP/gag DNA (DNA/DNA). Blood was
tions in blocking buffer starting at 1:100. The reaction was developed using
re examined starting at week 9 and then every 5 weeks for 7 months.
Table 2
Gag-specific IgG1 and IgG2a isotype responses
Vaccine Week 0 Week 5 Week 10 Week 13 Week 19
IgG1/IgG2a
rAAV
(LAMP)
0 0 0 0 0
rAAV
(LAMP/gag)
0 27 9 9 9
DNA-rAA V
(LAMP/gag)
0 >3 >27 27 27
DNA-DzNzA
(LAMP/gag)
0 1 1 1 1
Mice were injected im once with 1  109 particles of LAMP/gag rAAV
(AAV); primed with 50 Ag LAMP/gag DNA and boosted on day 21 with
1  109 particles of LAMP/gag rAAV (DNA/AAV); or injected twice with
50 Ag pITR/LAMP/gag DNA (DNA/DNA). The IgG antibody responses
were examined starting every 5 weeks for 5 months. Blood was collected by
tail bleed and serum samples were prepared in eight (3-fold) serial dilutions
in blocking buffer starting at 1:100. The reaction was developed using
biotinylated anti-mouse anti-IgG1 and IgG2a antibody conjugated with
avidin-horseradish peroxidase.
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DNA prime/rAAV boost group was 3-fold greater than the
DNA prime/boost group at week 9 and approximately 10-
fold greater at week 28. IgG1 and IgG2a isotype titers were
also measured on several occasions (Table 2). The DNA/
DNA prime/boost showed relatively equal IgG1 and IgG2a
response during the experiment. In contrast, both the
rAAV and DNA/rAAV groups showed high IgG1 and
relatively weak IgG2a responses that appear correlated in
time with the rAAV immunization. The results, together
with the stronger IL-4 responses, suggest that the rAAV
delivery steered the response toward a T helper type 2
response.Discussion
These studies document the effect of AAV-ITR DNA
sequences on Gag-specific immune responses of immunized
mice. Three genetic vaccine constructs encoding a LAMP-
Gag chimera were examined: (1) a standard pcDNA3.1
construct; (2) a comparable plasmid containing the expres-
sion elements bracketing the AAV ITR sequences (pITR);
and (3) the pITR plasmid encapsided as an rAAV vector.
Assays of early Gag-specific responses of mice immunized
with the pcDNA and pITR plasmids showed comparable
CD4+ IFN-g protein responses to the two plasmid constructs
whereas the antibody and CD8+ responses to the pI TR
construct were markedly greater. With mice injected four
times with the pITR/LAMP/gag construct (day 1 and 1, 2,
and 3 months later), the total IgG titer of blood samples taken
just before the third immunization was >100,000 and contin-
ued at that level through the last sample collected at 4 months.
This response was over 10-fold greater than that resulting
from immunization with pcDNA3.1/LAMP/gag DNA. The
CD8+ responses to the pITR plasmid construct were alsomarkedly greater with each of the three assays (IFN-g protein,
tetramer binding, and target cell lysis). Additionally, the
immune responses to the pITR LAMP/gag were long lasting.
After DNA immunization on days 1 and 21, the continued
presence of Gag-specific CD4+ memory T cells was readily
detected by IFN-g protein expression CD4+ responses in
week 23, 5 months after the last immunization. These same
mice developed an IgG titer of 72,900 at week 9 that slowly
declined through 28 weeks after immunization to a titer of
2700. Likewise, the CD8+ T cell IFN-g and tetramer
responses were detected 7 months after immunization.
The dichotomy between the equivalence of the early CD4+
responses to the pcDNA and pITR plasmids as compared to
the enhanced CD8+ and antibody responses to the pITR
plasmid is attributed to the unique disposition of the
LAMP/Gag chimera protein in transfected APCs and to the
differences in antigen epitope activation of CD4+and CD8+ T
cells, and B cells. Both confocal immunofluorescent locali-
zation (Marques et al., 2003) and ongoing immunoelectron
microscopy studies (data not shown) of cells transfected in
vitro validate that most of the LAMP/Gag protein is trafficked
in the endosomal–lysosomal pathway and in APCs is colo-
calized with endogenous LAMP and MHC II in specialized
vesicular compartments termed MHC class II-enriched com-
partment (MIIC). We propose that Gag class II epitope
activation of CD4+ T cell responses achieved by either the
pcDNA or pITR transgene constructs is because of LAMP-
targeting of Gag to the MHC II compartment. Optimal CD4+
Tcell responses require an initial MHC II presentation of high
doses of peptide epitopes while subsequent changes in the
transition from CD4+ naive to effector and to memory cells
are highly stable and there is limited or no requirement for
additional MHC II antigen epitope presentation (Hu et al.,
2001; Wherry et al., 2003). In contrast, CD8+ T cells and B
cells require continued antigen-specific expansion after pri-
mary infection or vaccination, with subsequent contraction in
the absence of antigen (Kaech et al., 2002; Wherry et al.,
2003). Prolonged exposure to antigen recruits more naive
precursors into the primary response and thus promotes and
sustain increased CD8+ T cell and antibody responses. While
the extent and duration of transgene LAMP/Gag protein
expression by transfected cells of immunized mice is un-
known, it is possible that the ITR sequences have a role in
mediating enhanced and prolonged antigen expression
whether encoded in plasmid DNA or that of the rAAV vector.
Whether this is related to gene integration or some other
function of ITR sequences is not known, but it possibly is
associated with a transcriptional function as has also been
suggested by Xin (2003).
The response to pITR/LAMP/gag as naked DNAwas also
compared to the plasmid construct packaged into the rAAV
vector delivery system. Many reports of gene therapy experi-
ments have shown that rAAV vectors result in efficient gene
delivery and long lasting expression of the transgene encoded
protein (Doe et al., 1996; Kessler et al., 1996; Xiao et al.,
1996; Manning, 1997). In principle, this is an attractive gene
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to prophylactic vaccines is complicated by the expected host
immune response to the AAV capsid protein that may limit
the effectiveness of repeated administration (Chirmule et al.,
2000) and the enhanced chromosomal integration of linear
DNAmolecules. In this study, to limit the effect of an immune
response to the vector, we restricted application of the rAAV
vector to protocols with a single injection, either as rAAV
(ITR/LAMP/gag) alone, or given as a boost following a
prime immunization with the pITR/LAMP/gag ‘‘naked’’
DNA plasmid. A comparison of the responses to the three
protocols, rAAValone (rAAV), DNA prime and rAAV boost
(DNA/rAAV), and the standard DNA prime, DNA boost
(DNA/DNA) showed greatly differing responses, especially
in the antibody and the duration of the responses. In general,
while the DNA/rAAV protocol elicited strong early (week 6)
responses, the maximum week 23 CD4+ and week 29 CD8+
responses were more consistently associated with the DNA/
rAAV protocol. Additionally, the DNA/rAAV immunization
elicited exceptionally high titer and long lasting Gag-specific
antibody response, with a peak of >218,700 at 9 weeks and
values of 24,300 continuing until at least 28 weeks. This was
accompanied by a profound shift in the IgG1/IgG2a ratio to 24
as compared to a ratio of 1 following the DNA/DNA
immunization. The high IgG1/IgG2a expression occurred
immediately after the single rAAV immunization as well as
after the rAAV immunization in the DNA-rAAV boost
protocol. IgG1 expression characteristically results from
activation of the Th2 subset of CD4+ T helper cells. Thus,
it appears that the rAAV vector as compared to naked DNA
preferentially drives a Th2 response. The basis of this
difference is not known. Possible explanations are an immune
response to the capsid protein, activation of innate immune
mechanisms by the virus-like vector, and transfection of a
different class of APC. The enhanced Th2 response to the
rAAV as compared to naked DNA, both encoding the same
transgene, is to our knowledge a novel finding. An additional
surprising finding was the relatively weak and transient
immune response to a single immunization with the rAAV
vector expressing the LAMP/Gag chimera, despite the pre-
sumed extended expression of the DNA. This weak primary
response to the rAAVvector was possibly the result of the low
dose of rAAVemployed (109). Others have reported a strong
and long-term humoral immune response to a single higher
dose (1011) injection of a rAAV vector encoding HIV-1 env,
tat, and rev genes (Xin et al., 2001).
In conclusion, this study suggests the effective applica-
tion of ITR sequences in HIV-1 LAMP/gag DNA vaccine
constructs. ITR-enhanced transgene expression and immu-
nogenicity of a ‘‘naked’’ HIV env DNA vaccine have also
recently been reported by Xin (2003). While there was no
significant effect on the early CD4+ T cell responses, the
pITR sequences resulted in long-term CD8+ and antibody
responses. The responses to the pITR plasmid differed
markedly from those to the rAAV vector, particularly in
the isotype, extent, and duration of antibody response,providing evidence for differences in the state or metabolic
fate of the single-stranded, linear, mammalian cell rAAV
vector DNA and the double-stranded, circular, E. coli DNA
of the pITR-LAMP/gag plasmid. The enhanced long-term
antibody response and Th2 phenotype of the DNA/rAAV
prime boost protocol could point to this use of an rAAV
boost as a preferred protocol under some circumstances, but
this is offset by the complications of producing and having
regulatory approval of two vaccine products, and the rec-
ognized chromosomal integration of the linear rAAV DNA.
As an alternative, multiple immunizations with the pITR/
LAMP/gag plasmid construct provide the means to achieve
high levels of both the antibody and cellular responses.
Current investigations of the response of monkeys to the
pITR/LAMP/gag construct have shown that each of the five
monkeys develops increasing antibody and T cell responses
through four immunizations. A critical question under
continuing investigation is whether the application of ITR
sequences as plasmid DNA avoids this complication of
chromosomal integration. To our knowledge, there are
currently no data showing the enhanced integration of
supercoiled, double-stranded DNA with the coding se-
quence bracketed by AAV-ITR sequences.Materials and methods
Plasmids
Eukaryotic expression plasmids were constructed using
nucleotides 1–1503 of the HIV-1 HXB2 p55gag gene
(GenBank , K03455) inserted in two vectors, pcDNA3.1
(Invitrogen) and pITR (Kessler et al., 1996), a vector con-
taining the adeno-associated virus inverted terminal repeat
(AAV-ITR) sequences flanking similar expression elements
(CMV promoter and BGH polyadenylation signal). The
plasmids shown in this study and as labeled in Fig. 1 are
(1) pcDNA3.1 gag and (3) pITR gag. In these plasmids, the
native gag sequence was inserted into theNheI andKpnI sites
of pcDNA3.1 and pITR vectors. (2) pcDNA3.1/LAMP/gag
and (4) pITR/LAMP/gag: these plasmids have an ORF of
2736 bp, inserted into the NheI and KpnI sites. They contain
1113 bp encoding the complete LAMP lumenal domain,
linked to gag at the 3Vend by XhoI, and gag adjoined to
LAMP transmembrane and cytoplasmic domains by EcoRI.
The plasmids used for vaccination were produced in E. coli
and made endotoxin-free (Qiagen, Valencia, CA).
Cell culture and rAAV vector production
The recombinant rAAV capsidated vectors were generated
using traditional methods (Manning et al., 1997). Briefly, the
vector plasmid pITR/LAMP/gag containing the AAV ITRs
was co-transfected with ACG2, a helper plasmid containing
the AAV coding region (AAV rep and cap genes) without the
ITRs, into adenovirus-infected human 293 cells. After 72 h,
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Tris–HCl, 150 mMNaCl, pH 8.0) by three cycles of freezing
and thawing. The extract was precipitated in sucrose and the
rAAV particles (rAAV-pITR LAMP/gag) purified twice by
ultracentrifugation in CsCl density gradient. The virions were
tested to be free of detectable replication-competent AAVand
of adenovirus by cytopathic bioassay. DNAse-resistant rAAV
titer was determined by quantitative PCR (qPCR) with virus
DNA samples prepared after digestion with proteinase K.
Briefly, 5 Al of the purified viral samples was protease K
treated and the DNA precipitated. The precipitated DNAwas
suspended 500 Al of distilled water. The DNA sample diluted
1:100 and 10 Al was used for the qPCR reaction. The HIV gag
gene region was amplified with primers 5V-AGGAGC-
CACCCCACAAGATTTA-3 V and 5 V- TGGCCG-
GGTCCTCCTACTC-3V to produce a 543-bp fragment of
the HIV-1 gag gene. The qPCR curves of rAAV-pITR-
LAMP/gag were related to a standard curve assessed by the
5 log spanning serial vector plasmid dilution (0.001–10 pg
DNA) and the number of genomic copies were calculated.
Typically, the vector titers were approximately 5  1012 to 1
 1013 DNAse-resistant particles per ml total RNA.
Analysis of protein expression
Human (293) cells were plated in 6-well plates (2  106
cells/well) and transfected with either plasmid DNA (4 Ag)
using the FuGENE 6 (Roche, Indianapolis, IN) transfection
reagent according to the manufacturerVs instructions or trans-
duced with the rAAV vector. The cells were harvested 48–72
h post-transfection and disrupted with lysis buffer [10 mM
Tris–HCL (pH 7.5), 150 mM NaCl, 1% sodium deoxycho-
late, 0.1% SDS, 1% Triton X-100, premixed protease inhib-
itors (Cfmplete, Roche Diagnostics GmbH, Mannheim,
Germany)], for 15 min on ice, and then cellular debris was
removed by centrifugation (Marques et al., 1998). Protein
concentration was determined by BCA (Pierce, Rockford,
IL). Samples were resolved on 10% polyacrylamide gels,
transferred onto Immobilon membranes (Millipore, Bedford,
MA), and then blocked in phosphate-buffered saline (PBS)
containing 5% non-fat dried milk. After washing with PBS-
Tween (0.05%), the blot was probed with mouse anti-Gag
(Dr. James Hildreth, Johns Hopkins School of Medicine,
Baltimore, MD) at 1:50 dilution for 2 h, washed three times,
and then incubated with peroxidase-conjugated goat anti-
mouse IgG antibody (Jackson ImmunoResearch Laboratories
Inc., West Grove, PA) at a 1:10,000 dilution for 1 h. Gag was
visualized by an enhanced chemiluminescence detection
system (Amersham Biosciences, Piscataway, NJ). Images
were digitally scanned and exported to Photoshop 5.0 (Ado-
be, San Jose, CA).
p24 Gag capture ELISA
Human (293) cells were plated in 6-well plates (2  106
cells/well) and transfected with plasmid DNA (4 mg) usingthe FuGENE 6 (Roche) transfection reagent according to the
manufacturerVs instructions. The cells were harvested 48–72
h post-transfection and disrupted with lysis buffer [10 mM
Tris–HCL (pH 7.5), 150 mM NaCl, 1% sodium deoxycho-
late, 0.1% SDS, 1% Triton X-100, premixed protease inhib-
itors (Cfmplete, Roche Diagnostics GmbH)], for 15 min on
ice, and then cellular debris was removed by centrifugation.
The cell lysates were stored at 4 jC for immediate use.
Purified anti-Gag M1 IgG (Dr. James Hildreth, Johns Hop-
kins School of Medicine) was diluted in 50 mM Tris buffer,
pH 9.5, at a concentration of 10 Ag/ml and 50 Al of the
solution was added to each well of a 96-well plate (Nunc,
Roskilde, Denmark). After overnight incubation at 4 jC, the
solution was removed and the plates were washed six times
with PBS containing 0.05%Tween 20wash buffer. The plates
were incubated for 2 h at 37 jCwith 200 Al of blocking buffer
(3% BSA in PBS) and then washed eight times. HIV-Gag p24
standards and cell lysate samples were prepared in standard
antigen dilution buffer (RPMI 1640, 10% FBS, 1.0% Triton
X-100). Each dilution (100 Al) was added to the blocked
plate, and the plates were incubated overnight at 4 jC.
Biotinylated anti-p24 polyclonal IgG antibody (Dr. James
Hildreth, Johns Hopkins School of Medicine) diluted 4000-
fold in diluent buffer (5% normal goat serum, 1% BSA, and
0.05% Tween 20 in PBS) was added to each well and
incubated for 2 h at room temperature. The plates were
washed eight times with wash buffer followed by incubation
with streptavidin-peroxidase conjugate diluted 5000-fold in
diluent buffer for 30 min at room temperature. The plates
were washed eight times in wash buffer. Turbo tetramethyl-
benzone (TMB) substrate solution (BD PharMingen, San
Diego, CA) was added to each well and incubated for 15 min
at room temperature. The reaction was stopped by adding 100
Al of 1 M sulfuric acid, and absorbance at 450 nm was
measured in a BIO-RAD 3550-microplate reader.
Animals and immunization
Groups of 8–10 female (6–8 weeks old) BALB/c mice
(Charles Rivers, Wilmington, MA) were immunized intra-
muscularly (im) with 50 Ag of the specified ‘‘naked’’ DNA
plasmid and the mice were boosted after 3-week interval with
the same antigen as ‘‘naked’’ DNA or as capsidated rAAV. In
addition, naive mice received a single immunization with the
indicated rAAV. The rAAV vectors were diluted in PBS to
109–1011 particles/ml and 100 Al (108–1010 virions) of rAAV
was administered im in each mouse.
Antibody responses of vaccinated mice
Blood was collected by tail bleed and centrifuged to
remove cells, and the serum collected and stored at 4 jC
for immediate use. HIVIIIB lysate (ABI, Rockville, MD) was
diluted in 0.1 M sodium carbonate–bicarbonate buffers, pH
9.4 (Pierce) at a concentration of 5 Ag/ml and 50 Al of the
solution was added to each well of a 96-well plate (Nunc).
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the plates were washed six times with PBS containing 0.05%
Tween 20 wash buffer. The plates were incubated for 2 h at 37
jC with 200 Al of blocking buffer [PBS with 0.05% Tween-
20 and 5% Fetal bovine serum (FBS)] and then washed three
times. Serum samples were prepared in eight (3-fold) serial
dilutions in blocking buffer starting at 1:100. Each dilution
(100 Al) was added to the blocked plate, and the plates were
incubated overnight at 4 jC. For IgG detection, the reaction
was developed using goat anti-mouse anti-IgG horseradish
peroxidase (Cappel, Durham, NC) at a 1:5000 dilution. For
IgG1 and IgG2a, biotinylated anti-mouse anti-IgG1 and IgG2a
antibody (BD PharMingen) diluted 1:500 was conjugated
with avidin-horseradish peroxidase (BD PharMingen) diluted
1000-fold, and 100 Al was added to each well for 2 h at 37 jC.
Turbo tetramethylbenzone (TMB) substrate solution (BD
PharMingen) was added to each well and incubated for 15
min at room temperature. The reactionwas stopped by adding
100 Al of 1 M sulfuric acid, and absorbance at 450 nm was
measured in a BIO-RAD 3550-microplate reader.
Preparation of splenocytes for T-cell-mediated immune
responses
Single-cell suspensions, depleted of red blood cells
(RBC), were prepared from freshly isolated splenocytes in
culture medium (RPMI medium 1640 supplemented with
5% v/v FBS, 100 units/ml penicillin/streptomycin, 2 mM L-
glutamine, 50 AM 2-mercaptoethanol, and 0.01 M HEPES
buffer). Splenocytes were counted and suspended at a
concentration of 10  106 cells/ml of the culture medium
for T cell-mediated assays.
Real-time quantitative RT-PCR detection of IL-4 cytokine
upregulation
Splenocytes of immunized mice were co-cultured with
feeder cells (splenocytes from naive mice irradiated with
3500 rad) in the presence of 10 Ag/ml HIVSF2 p55 Gag
recombinant protein (Baculovirus-produced, National Insti-
tutes of Health AIDS Research and Reference Reagent
Program, Rockville, MD), 5 Ag/ml concanavalin A (Sigma,
St. Louis, MO), or in culture medium alone, in duplicates,
in a 48-well plate cultured overnight for cytokine mRNA
detection. After overnight culture, the cells were washed
with PBS supplemented with 2% FBS and 100 units/ml
penicillin/streptomycin and resuspended in 100 Al of RNA-
later (Ambion, Austin, TX) and frozen until further pro-
cessing. Total RNA was then extracted using RNeasy kits
(Qiagen) according to the manufacturer ’s protocol. The
cDNA was made using the Ready-To-Go, T-primed first
strand kit (Amersham Pharmacia Biotech Inc., Piscataway,
NJ) according to manufacturer ’s protocol starting from 5
Ag of the extracted RNA from each sample. The primers
used for the detection of HPRT and IL-4, and the cycling
conditions are described in Reiner et al. (1993). Forstandards, the pPQRS plasmid (containing HPRT, INF-g,
IL-2, IL-4, IL-5, IL-10, IL-12, TNF-A, TGF-b, and iNOS
inserts) was diluted from the original stock to 10,000,
1000, 100, 10, 1, and 0.1 fg/Al dilutions in sterile distilled
water. The cDNA of the samples was diluted at 1/20 in
sterile distilled water. The PCR amplification was per-
formed on an iCycler iQ Multi-color real-time PCR detec-
tion system (BioRad laboratories Inc., Hercules, CA)
allowing automatic collection of the florescence emission
data. The reaction mixture contained 2 solution of SYBR
Green PCR Master Mix (PE Biosystems, Foster city, CA),
10 dual (forward and reverse) primer mixture (0.25 AM
of each primer), and standards or samples (10 Al/well) in
duplicate, in a final volume of 50 Al. Cycling conditions
consisted of an activation step at 95 jC for 2 min, followed
by 45 cycles of 40 s of denaturing at 95 jC, 20 s of
annealing at 60 jC, 40 s of extension at 72 jC, and a final
extension for 10 min at 72 jC. The cytokine expression
levels of each sample, run in duplicate, were normalized by
hypoxanthine-guanine phosphoribosyltransferase (HPRT)
mRNA. The results are expressed as 100  cytokine-
mRNA/HPRT mRNA.
ELISA analysis of splenocyte IFN-c production
Splenocytes of immunized mice were cultured as de-
scribed above in triplicate in a 96-well plate and the culture
supernatants were harvested after 72 h for the detection of
secreted IFN-g as measured by OPTEIA ELISA kits (BD
PharMingen).
CD8+-mediated T-cell responses of immunized mice
Gag-specific CD8+-mediated responses were measured
after a single naked DNA or a combination of ‘‘naked’’ DNA
and rAAV immunization followed by in vivo expansion of
Gag-activated T cells through inoculation with recombinant
vaccinia-gag-pol (rVVgag-pol; 107 plaque-forming units,
intraperitoneal). Five days later, mice were injected with 10
Ag of an immunodominant H2Kd-restricted Gag peptide
epitope (position 65–73, AMQMLKETI) intravenously,
and 2 h later they were sacrificed and splenocytes were
collected.
51Cr release assay
P815 target cells (2 106/ml) were pulsed overnight with
10 AM p55Gag peptide AMQMLKETI in culture medium.
Target cells were labeled with 50 mCi/ml of [51Cr]Na2CrO4
(Amersham Biosciences) for 2 h. The cells were then washed
three times, resuspended in culture medium, and diluted to
2 105 cells/ml. The target cells (1104) were seeded onto a
U-bottom 96-well plates with equal volumes of 2% Triton
(maximum release), media alone (minimum release), or a
suspension of splenocytes from mice immunized for Gag-
specific CD8+-mediated responses (effector cells) at different
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4-h incubation at 37 jC, 50 Al of supernatant was transferred
to a LumaPlate (Packard,Meriden, CT), dried, and counted in
a scintillation counter TOPCOUNT NXT scintillation count-
er (Packard). The percentage of specific lysis (percent killing)
was calculated as 100  [(cpm released with effector) 
(minimum release)] / [(maximum release)  (minimum
release)].
Tetramer staining
Splenocytes from immunizedmice were washed in FACS-
can buffer at 4 jC and blocked with anti-mouse CD16/CD32,
FcgIII/II receptor antibody, at a concentration of 10 Ag/ml
(BD PharMingen) for 10 min at 4 jC. The splenocytes (1 
106 cells/well) are stained in duplicate with PE-conjugated
Tetramer (H-2Kd/AMQMLKETI; NIAID, National Institutes
of Health, Atlanta, GA) and the immunoglobulin isotype
control rat IgG1 antibody (BD PharMingen) at a dilution of
1:100 for 1 h at 4 jC. The cells are washed twice with
FACScan buffer and incubated with the secondary antibody
FITC-conjugated rat anti-mouse CD8 (BD PharMingen) at a
dilution of 1:100 for 30 min at 4 jC. Finally, the cells were
washed twice with FACScan buffer. Analysis was done on a
BD Biosciences FACScan with CellQuest software. A min-
imum of 200,000 events were analyzed and the results were
expressed as percentage of tetramer-binding cells on total
CD8+ cells.
Intracellular IFN-c staining
Intracellular IFN-g staining was performed using the
Cytofix/Cytoperm Plus (with GolgiStop) kit (BD PharMin-
gen). Briefly, golgistop containing monensin was added to
the splenocytes harvested from the immunized mice for 2 h at
37 jC. After incubation, cells were washed twice with
FACScan buffer and nonspecific binding was blocked by
incubating cells with anti-FcgR antibody (BD PharMingen)
at a concentration of 10 Ag/ml for 10 min at 4 jC. The
splenocytes (1106cells/well) were stained in duplicate with
FITC-conjugated rat anti-mouse CD8 antibody (BD Phar-
Mingen) at a dilution of 1:100 for 30 min at 4 jC. The cells
were washed twice with FACScan buffer and resuspended in
200 Al Cytofix/Cytoperm solution at 4 jC for 20 min. Cells
were then washed twice with Perm/Wash solution and stained
with PE-conjugated rat anti-mouse IFN-g antibody or the
immunoglobulin isotype control rat IgG1 antibody (BD
PharMingen) diluted 1:100. Analysis was done on a BD
Biosciences FACScan with CellQuest software. A minimum
of 200,000 events were analyzed and the results were
expressed as percentage of IFN-g+ cells on total CD8+ cells.
Statistical analyses
Unpaired t test analyses and all graphs were made using
StatView 5.0 (SAS Institute Inc. Cary, NC).Acknowledgments
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